Although bFGF has been shown to promote the in vitro motility of tumour cells, such as prostate cancer cells and melanoma cells (Kwabi-Addo et al, 2004; Chalkiadaki et al, 2009), this is the first report that describes the effects of bFGF on the motility of ESFT cells. Here, FGF2 is linked to prostate carcinoma.